Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Authors
Keywords
-
Journal
BMC Cardiovascular Disorders
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-07
DOI
10.1186/s12872-020-01827-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Evolocumab on Lipoprotein Particles
- (2018) Peter P. Toth et al. AMERICAN JOURNAL OF CARDIOLOGY
- Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
- (2018) Michel R. Langlois et al. CLINICAL CHEMISTRY
- Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by 1H NMR Spectroscopy in a Multilaboratory Trial
- (2018) Beatriz Jiménez et al. ANALYTICAL CHEMISTRY
- Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome
- (2018) Guglielmo Gallone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension
- (2018) Lars Harbaum et al. THORAX
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or PlaceboCLINICAL PERSPECTIVE
- (2015) Samia Mora et al. CIRCULATION
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision High-Throughput Proton NMR Spectroscopy of Human Urine, Serum, and Plasma for Large-Scale Metabolic Phenotyping
- (2014) Anthony C. Dona et al. ANALYTICAL CHEMISTRY
- All Low-Density Lipoprotein Particles Are Not Created Equal
- (2014) Ronald M. Krauss ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
- (2014) Eli M. Roth et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events
- (2013) Samia Mora et al. CIRCULATION
- Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices
- (2013) T. G. Cole et al. CLINICAL CHEMISTRY
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤ 40 years of age)
- (2011) Georg Goliasch et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
- (2011) James D. Otvos et al. Journal of Clinical Lipidology
- Small dense LDL particles - a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study
- (2011) Anne P Toft-Petersen et al. Lipids in Health and Disease
- Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry
- (2008) Keith AA Fox et al. Nature clinical practice. Cardiovascular medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now